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ABSTRACT
Background. Kidney donation is associated with few adverse outcomes in living donors.
The aim of this study was to evaluate the outcomes of living kidney donors and the utility
of creatinine-based equations to predict chronic kidney disease.
Methods. The study population was selected among 154 living kidney donors from 2001
to 2009. Seventy-eight patients underwent medical consultation to review demographic
data and perform laboratory evaluations. Estimated glomerular filtration rate (GFR)
values were obtained by three equations: Modification of Diet in Renal Disease (MDRD),
Cockcroft-Gault (C-G) and Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI). Receiver operating characteristic (ROC) analysis was performed to determine the
area under the curve of each equation to predict evolution to chronic kidney disease.
Results. The overall median age was 39 years including 64% of women subjects. The
mean follow-up after kidney donation was 65  34 months. During follow-up, 20.5% of
patients developed hypertension. Serum creatinine values above 1.5 mg/dL were detected in
14.1% of cases. Dyslipidemia was present in 33.3% of donors at the last follow-up. According
to measured creatinine clearance and the C-G equation, only four and six donors had renal
failure (defined as GFR  60 mL/min), a number that increased to 23 (29.4%) when
considering the MDRD or CKD-EPI equations (P  .05). ROC curves performed to explore
the GFR measurements to predict renal failure occurrence after donation showed the
CKD-EPI to be the only one with a significant area under the curve (0.7442, P  .003).
Conclusion. Living kidney donors should receive careful long-term follow-up. Assess-
ment of renal function before donation using CKD-EPI creatinine-based equations must
be performed preferentially. A careful approach should be adopted for the detection and
treatment of other complications such as hypertension and dyslipidemia.
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sKIDNEY TRANSPLANTATION is considered thebest available treatment for patients with end-stage
renal disease, mainly because it improves the quality of life
and prolongs survival when compared with waiting list
patients who remain on dialysis.1 The favorable balance of
recipient benefit and donor risk make living donor kidney
transplantation a common practice worldwide. Many stud-
ies have confirmed the long-term safety of kidney donation.
Advances in surgical techniques (ie, laparoscopic kidney
donations) have improved the procedure-associated mor-
bidity.1,2
Renal tissue reduction is accompanied by compensatory
hyperfiltration by the remaining nephrons with increases in
single-nephron glomerular filtration rates (GFR). This pro-
cess can lead to proteinuria, interstitial fibrosis, and a
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Transplantation Proceedings, 43, 2481–2486 (2011)rogressive decline in global GFR. Although living kidney
onation is a safe procedure with little or no added risk to
he donor of end-stage renal failure,3 recent studies have
uggested that even modest declines in kidney function are
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2482 LIBÓRIO, BARROS, ESMERALDO ET ALassociated with greater risks of cardiovascular disease and
death.4
Preexisting chronic kidney disease is the main risk factor
for a progressive decline in renal function. Careful evalua-
tion of potential living kidney donors must include an
assessment of GFR. Inulin clearance is the gold-standard
procedure to measure GFR, but limited access to inulin and
the cumbersomeness of the technique have led this method
to be abandoned for practical evaluation. Radioisotope
methods such as iohexol or 51Cr-EDTA are costly and not
widely available, especially in the developing world. Serum
creatinine is a widely used, low-cost method, but shows
dependence on muscle mass, generation, and tubular secre-
tion rendering it inaccurate.5
Several creatinine-based formulas have been developed
to predict GFR. The first widely used for clinical practice
was the Cockcroft-Gault (C-G) equation, which considers
the weight, sex, and age of the patient.6 In the last decade,
another equation has shown to be more accurate for
patients with chronic kidney disease, the Modification of
Diet in Renal Disease (MDRD) equation, which in its
simplified version (sMDRD) takes into account the age,
sex, and race of the subject. Recently, a new equation—
Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI)—has been proposed to estimate GFR, since it
is as accurate as the MDRD for a GFR value less than 60
mL/min but shows a better performance for the group of
subjects with GFR values greater than 60 mL/min.6–8
Measured creatinine clearance using 24-hour urine col-
lections (CrCl) have shown to overestimate the real GFR,
especially due to tubular secretion of creatinine. Despite its
poor performance, CrCl is typically used as a surrogate
measure of GFR. Most centers have arbitrarily selected 80
mL/min per 1.73 m2 as a GFR threshold, below which there
s no donation by a living donor.9
Many studies have evaluated various estimates of GFR
using gold-standard methods, generally with radioisotopes,
but their association has scarcely been studied for progres-
sion to chronic renal disease.3,10,11 In fact, prediction of the
possibility of progressive renal failure is the most suitable
endpoint when evaluating potential kidney donors. In the
present study, we examined the power of predonation CrCl
and the most commonly used creatinine-based formulae to
predict a subsequent decline in renal function.
MATERIALS AND METHODS
Patient Population
Our Ethical Board approved the protocols. The study population
was selected from 154 living kidney donors from 2001 to 2009.
After all patients had been contacted and informed about the
study, 78 underwent the medical consultation to review demo-
graphic data and measure blood pressure, body mass index (BMI),
and other comorbidities. Blood samples and 24 hour urine collec-
tions were obtained for biochemical analysis, total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, urinalysis, and protein excretion. Measured CrCl ewas calculated according to: ClCr  Urine creatinine (mg/dL) 
rinary flux (mL/min)/serum creatinine (mg/dL).
Estimation of GFR
All analyses were performed in our Central Laboratory with serum
creatinine determinations using a kinetic Jaffe assay to minimize
noncreatinine chromogens.
Estimated GFR was obtained by three equations:
1. sMDRD equation: GFR (expressed in mL/min/1.73 m2) 
186  [Pcr]1.154  [age]0.203  [0.742 if the patient is female]
2. C-G formula normalized to a body surface area (BSA) of 1.73
m2, (CrCl, expressed in mL/min/1.73 m2): GFR (males) 
1.23  weight (kg)  [140  age]/plasma creatinine
(mol/L)  1.73/BSA, GFR (females)  1.03  weight
(kg)  [140  age]/plasma creatinine (mol/L)/1.73/BSA,
where BSA (m2)  [weight (kg)  height (cm)/3600].
3. CKD-EPI formula using following equations:
For women with creatinine  0.7 mg/dL (62 mmol):
GFR 144 (creatinine ⁄ 0.7)0.329 (0.993)age.
For women with creatinine  0.7 mg/dL (62 mmol):
GFR 144 (creatinine ⁄ 0.7)1.209 (0.993)age.
For men with creatinine  0.9 mg/dL (80 mmol):
GFR 144 (creatinine ⁄ 0.9)0.411 (0.993)age.
For men with creatinine  0.9 mg/dL (80 mmol):
GFR 144 (creatinine ⁄ 0.9)1.209 (0.993)age.
All patients were considered nonblack due to the special miscege-
nation of our population.
Statistical Analysis
All data are expressed as mean values  standard deviations. The
analysis was performed using SPSS 16.0 and GraphPad Prism 5 for
Mac. Paired Students t tests were used to compare pre- and
ostdonation data and unpaired Students t tests to compare
ontinuous variables between groups. Categorical variables were
nalyzed by the chi-square test. Discrimination, that is, the model’s
bility to differentiate between patients who died and those who
urvived, was examined using the area under a receiver operating
haracteristic curve (AUROC). To compare the areas under two
UROC curves, we used a nonparametric approach. AUROC
nalysis was also performed to calculate cutoff values, sensitivity,
pecificity, overall correctness, as well as positive and negative
redictive values. Finally, cutoff points were calculated by obtaining
he best Youden index (sensitivity  specificity  1).
RESULTS
Patient Characteristics Before and After Kidney Donation
Among 78 patients suitable for analysis, 50 (64%) were
women. The overall age at transplantation ranged from 19
to 59 years (median, 39). Fifty-eight kidney donors were
first or second-degree relatives of their recipients. As part
of the exclusion criteria for donation, no subject had a
blood pressure above 140  90 mm Hg or a protein
xcretion greater than 150 mg/24 h in the pretransplanta-
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RENAL FUNCTION AFTER KIDNEY DONATION 2483tion evaluation. Ten patients underwent a conventional
open nephrectomy and the offers a laparoscopic procedure.
Only one patient had a right kidney removal. The mean
follow-up after kidney donation was 65  34 months. Table
Table 1. Donor Characteristics
Before Donation After Donation P
Systolic blood pressure
(mm Hg)
114  11 128  18 .03
Diastolic blood pressure
(mm Hg)
76  9 79  11 .18
Protein excretion (mg/
24 h)
61.1  9.5 92.5  21.8 .48
Blood glucose (mg/dL) 90.1  2.5 88.1  1.1 .42
Hemoglobin (g/dL) 13.4  0.4 13.9  0.2 .15
Uric acid (mg/dL) 3.8  0.2 5.1  0.2 .003
BMI (kg/m2) 25.4  0.4 24.9  0.9 .60
otal cholesterol
(mg/dL)
177  14 188  12 .42
DL cholesterol (mg/dL) 119.0  9.8 123.6  10.7 .43
DL cholesterol (mg/dL) 37.3  3.8 42.3  3.5 .45
riglycerides (mg/dL) 103.3  10.3 153.2  10.9 .10
erum creatinine
(mg/dL)
0.92  0.02 1.14  0.03 .0001
easured CrCl (mL/min) 124.6  9.46 86.2  3.2 .0001
stimated CrCl, C-G
(mL/min)
94.3  3.1 76.8  4.3 .001
stimated GFR, MDRD
(mL/min)
87.2  2.9 68.1  3.0 .0001
stimated GFR, CKD-
EPI (mL/min)
91.8  2.6 70.7  2.5 .0001
BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; ClCr, creatinine clearance; C-G, Cockcroft-Gault; GFR, glomerular
filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
Table 2. Predonation Clinical and Laboratory Char
Age (y)
ender (M/F)
Follow-up (mo)
Predonation systolic blood pressure (mm Hg)
Predonation diastolic blood pressure (mm Hg)
Predonation protein excretion (mg/24 h)
Predonation blood glucose (mg/dL)
Predonation hemoglobin (g/dL)
Predonation uric acid (mg/dL)
Predonation BMI (kg/m2)
Predonation total cholesterol (mg/dL)
Predonation LDL cholesterol (mg/dL)
Predonation HDL cholesterol (mg/dL)
Predonation Triglycerides (mg/dL)
Predonation serum creatinine (mg/dL)
Predonation measured CrCl creatinine clearance (mL/min)
Predonation CrCl, C-G (mL/min)
Predonation estimated GFR, MDRD (mL/min)
Predonation estimated GFR, CKD-EPI (mL/min)BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein; C
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.details the demographic data of the sample pre- and
ostdonation.
During follow-up, 16 patients (20.5%) developed hyper-
ension, but there was no new case of diabetes mellitus.
erum creatinine values greater than 1.5 mg/dL were
etected in 11 (14.1%) patients. Dyslipidemia, defined as
DL cholesterol greater than 130 mg/dL or triglycerides
bove 150 mg/dL, was present in 26 (33.3%) donors at last
ollow-up.
According to the measured CrCl and C-G equation, only
our and six donors had renal failure (defined as GFR  60
L/min) at last follow-up, respectively. This number in-
reased to 23 (29.4%) when considering sMDRD or CKD-
PI equations (P  .05, chi-square).
Estimated GFR Pretransplantation Predicting Evolution to
Renal Failure
The patients after donation were then classified as devel-
oping or not renal failure (GFR  60 mL/min). Due to the
greater concordance between sMDRD and CKD-EPI equa-
tions, these parameters were adopted in considering GFR
after nephrectomy. Patients developing renal failure had a
shorter follow-up than the others (47.0  7.1 vs 63.7  6.6
onths, P  .12). The only difference in demographic and
linical data, other than measurements of renal function,
etween donors developing or not renal failure was age:
1.9  2.4 vs 34.0  1.5, respectively (P  .006; Table 2).
Regarding pretransplantation renal function, no differ-
ence was observed in measured CrCl. However, donors
developing renal failure showed a trend toward higher
serum creatinine values before donation, just as a lower
istics of Donors According to GFR After Donation
FR  60 mL/min
(n  55)
GFR  60 mL/min
(n  23) P
34.0  1.5 41.9  2.4 .006
19/36 9/14 .79
63.7  6.6 47.0  7.1 .12
112  3.6 117  5.3 .40
75  2.7 77  5.3 .67
62.5  13.2 47.1  9.9 .42
88.1  3.9 94.0  2.4 .29
13.2  0.5 13.8  0.4 .44
119.0  9.8 123.6  10.7 .43
25.2  0.4 25.7  0.6 .52
169  29 185  19 .63
114  9 119  12 .56
38.1  12 34.7  13 .71
89  15 117  9 .17
0.86  0.03 0.96  0.04 .06
127  10 126  19 .98
100  3.6 87  5.4 .04
92  2 80  4 .03
96  3 84  4 .03acter
GlCr, creatinine clearance; C-G, Cockcroft-Gault; GFR, glomerular filtration rate;
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2484 LIBÓRIO, BARROS, ESMERALDO ET ALGFR when estimated by C-G, sMDRD, or CKD-EPI
(Table 2).
Receiver operating characteristic (ROC) curves were
performed to explore the different GFR measurements to
predict renal failure occurrence after donation. CKD-EPI
was the only GFR measurement showing a significant area
under the curve (AUC: 0.7442, P  .003). Measured CrCl,
C-G equation, and sMDRD formula had similar AUC
values, but none of them was significantly able to differen-
Fig 1. Receiver operating characteristic comparing area under
he curve of the Chronic Kidney Disease Epidemiology Collab-
ration (CKD-EPI) with other glomerular filtration rate estimation
Table 3. Discrimination for Different Formulae Estimating GFR
in Predicting Evolution to Renal Failure
AUC 95% Confidence Interval P
Measured creatinine
clearance
0.5739 0.3940–0.7539 .42
ockcroft-Gault 0.6036 0.4541–0.7532 .17
implified MDRD 0.6127 0.4502–0.7752 .17
KD-EPI 0.7442 0.6069–0.8814 .003
GFR, glomerular filtration rate; AUC, area under the curve; MDRD, Modifica-
tion of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration.ethods. mDRD, Modification of Diet in Renal Disease.tiate patients developing or not developing renal failure
(Table 3). Figure 1 displays graphs comparing CKD-EPI
with other formulas to predict renal failure.
The cutoff with the best accuracy, according to the
Youden index, of GFR was estimated by CKD-EPI, at 85
mL/min, namely, a sensitivity of 60% and a specificity of
80%. Figure 2 displays the evolution of renal function
among patients with a predonation CKD-EPI eGFR less
than 85 mL/min. The mean follow-up among this group was
49  4 months.
DISCUSSION
In this research, the CKD-EPI formula was the only GFR
estimate able to predict the evolution to renal failure
among a cohort of living kidney donors after long-term
follow-up when compared to measured CrCl, C-G, and
sMDRD formulae.
Living donor transplantations are associated with bet-
ter outcomes compared with cadaveric donor proce-
dures.1 Long-term survival for patients and allografts
from living donors are excellent; the survival rates are
higher than 80% at 10 years with normal life expectancy
and quality of life in the donors.12 For this reason, there
has been an increased number of living kidney trans-
plants, which now comprise around 40% of all proce-
dures in some regions,13,14 while others achieve more
than 80% of cases.15 Moreover, surgical techniques are
becoming better, with fewer postoperative complications,
primarily with laparoscopic methods.2 Long-term medi-
al complications, however, must be taken into account
hen considering living kidney donation. Kidney dona-
ion can be associated with, a progressive GFR decline
nd consequently chronic renal disease.3
We present a cohort of living kidney donors in a large
center in Brazil. The studied patients had no comorbidity
prior to kidney donation, and during follow-up, a signif-
icant proportion of patients developed hypertension and
Fig 2. Evolution of patients with a Chronic Kidney Disease
Epidemiology Collaboration estimated glomerular filtration rate
(CKD-EPI eGFR) less than 85 mL/min.hypercholesterolemia. Renal failure potentiates the ad-
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Controversies about living kidney donation have
emerged from the long-term evolution. Opponents of
this practice point suggest that living kidney donation is
a risk to the donor, risks that do not justify the benefits to
the recipient.1
A study of 1278 Canadian kidney donors showed that
donors were more likely to receive a diagnosis of hyperten-
sion, possibly because of more careful follow-up when
compared with controls, but they can in fact have a higher
risk of hypertension than the general population.10 Hyper-
tension developed in 20.5% of the present patients, similar
to the rate observed in other studies.16 It can lead to
yperfiltration in the remaining kidney, accelerating glo-
erulosclerosis. Obesity has been suggested to be the main
ndependent risk factor for development of hypertension
fter kidney donation.17
Dyslipidemia was detected in more than 30% of cases,
showing an additional cardiovascular risk in this population,
which could be responsible for increasing future mortality.
Dyslipidemia postdonation was also associated with obese
donors in another study.17 The burden of cardiovascular
isk factors after donation can influence the overall prog-
osis of kidney donors, especially when associated with
enal failure.
Posttransplantation the serum creatinine was elevated in
significant proportion of patients (14.1%). However,
mploying creatinine-based formulae (sMDRD or CKD-
PI equations) to predict chronic renal disease, the per-
entage of patients with reduced GFR increased to 29.4%.
hese findings showed the importance of using creatinine-
ased equations in the follow-up of kidney donors. While
MDRD and CKD-EPI had greater similarity in classifying
idney donors according to the presence of renal failure,
he sMDRD formula was inferior to the CKD-EPI when
valuating these donors predonation to predict evolution to
hronic renal failure.
In the original study,8 CKD-EPI and MDRD showed
similar accuracy when evaluating patients with reduced
GFR, but CKD-EPI was better when applied to persons
with normal renal function, a clinical scenario similar to
predonation. Our data suggested that this better perfor-
mance in the normal GFR range was applicable to predict
GFR decline over postdonation follow-up.
The AUC achieved by CKD-EPI was far from the ideal,
pointing out that other factors must be evaluated before
donation, such as hypertension, BMI, and protein excretion
to minimize evolution to renal failure. The cutoff point (85
mL/min) is high even with this cutoff, it shows a relatively
low sensitivity (60%). It was not the intention of this study
to determine the estimated GFR that determined suitability
for kidney donation.
The greater limitation of our study was the lack of a
standard GFR measurement. Some studies have used ra-
dioisotopic tracers to determine GFR. In a recent study of
253 living kidney donors, the MDRD, C-G, and CKD-EPI
equations were compared with measured GFR (I-iothal-mate). All equations underestimated measured GFR be-
ore donation, especially at higher levels of GFR.18 Despite
this limitation, creatinine-based formulae are still widely
used for association with cardiovascular outcomes. More-
over, the greater agreement between sMDRD and CKD-
EPI to classify patients with GFR 60 mL/min ameliorated
the validity of data.
In summary, living kidney donors should undergo careful
long-term follow-up. The CKD-EPI must be preferred
when using creatinine-based equations predonation, due to
its potential to predict a subsequent decline in renal func-
tion.
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